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Available online 16 June 2020The original designation of “Arrhythmogenic right ventricular (dysplasia/) cardiomyopathy”(ARVC)was used by
the scientists who first discovered the disease, in the pre-genetic and pre-cardiac magnetic resonance era, to
describe a new heartmuscle disease predominantly affecting the right ventricle, whose cardinal clinicalmanifes-
tationwas the occurrence ofmalignant ventricular arrhythmias. Subsequently, autopsy investigations, genotype-
phenotype correlations studies and the increasing use of contrast-enhancement cardiac magnetic resonance
showed that the fibro-fatty replacement of the myocardium represents the distinctive phenotypic feature of
the disease that affects the myocardium of both ventricles, with left ventricular involvement whichmay parallel
or exceed the severity of right ventricular involvement. This has led to the new designation of “Arrhythmogenic
Cardiomyopathy” (ACM), that represents the evolution of the original term of ARVC. The present International
Expert Consensus document proposes an upgrade of the criteria for diagnosis of the entire spectrum of the phe-
notypic variants of ACM. The proposed “Padua criteria” derive from the diagnostic approach to ACM, which has
been developed over 30 years by the multidisciplinary team of basic researchers and clinical cardiologists of the
Medical School of the University of Padua. The Padua criteria are a working framework to improve the diagnosis
of ACM by introducing new diagnostic criteria regarding tissue characterization findings by contrast-enhanced
cardiac magnetic resonance, depolarization/repolarization ECG abnormalities and ventricular arrhythmia fea-
tures for diagnosis of the left ventricular phenotype. The proposed diagnostic criteria need to be further validated
by future clinical studies in large cohorts of patients.
© 2020 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).racic and Vascular Science, Via
o).
. This is an open access article under1. Introduction
The original designation of “Arrhythmogenic right ventricular (dys-
plasia/) cardiomyopathy (ARVC)” was used by the scientists who first
discovered the disease, in the pre-genetic and pre-cardiacmagnetic res-
onance (CMR) era, to describe a new heart muscle disease predomi-
nantly affecting the right ventricle (RV), whose cardinal clinicalthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
107D. Corrado et al. / International Journal of Cardiology 319 (2020) 106–114manifestation was the occurrence of malignant ventricular arrhythmias
[1–6]. Subsequently, autopsy investigations, genotype-phenotype cor-
relations studies and the increasing use of contrast-enhancement CMR
(CE-CMR) showed that the fibro-fatty replacement of the myocardium
represents the distinctive phenotypic feature of the disease and affects
not only the RV but also the left ventricle. (LV) [2,6–10]. In the last de-
cade there have been several pathologic and clinical studies that charac-
terized the structural and electrical findings of the LVdisease phenotype
(Fig. 1) and provided significant insights into diagnosis of left-sided dis-
ease [9–18]. This has led to the new designation of “ArrhythmogenicFig. 1. Electrocardiographic, CE-CMR imaging, and histological features of a representative pa
voltages in limb leads and flattened T-waves in the inferolateral leads (A). Post-contrast CM
subepicardial LGE (white arrows) involving the LV free wall (boxed area) and septum (“rin
showing fibro-fatty myocardial replacement affecting the subepicardial LV layer (Heidenhain
fatty tissue (E.E stain) (E). ACM = arrhythmogenic cardiomyopathy; CMR = cardiac magnet
ventricular. From Cipriani et al. [18].Cardiomyopathy (ACM)” that represents the evolution of the original
term ARVC and reflects the modern concept of a biventricular muscle
disease with LV involvement which may parallel or exceed the severity
of RV involvement [19]
A recent International Expert Report has provided an extensive crit-
ical reviewof the clinical performance of the available diagnostic criteria
for ACM and identified potential areas of improvement [2]. Major limi-
tations of the current approach to the disease diagnosis addressed by
the document include: (i) the incomplete understanding of the genetic
background of the disease and the large genetic noise due to severaltient with a predominant-left ACM related to a DSP gene defect. Basal ECG showing low
R images in long-axis (B) and short-axis (C) views showing normal LV cavity size and
g-like” pattern), from basal to apical regions. Histologic examination of the boxed area
trichrome stain) (D); close up detailing residual myocytes embedded within fibrous and
ic resonance; DSP = Desmoplakin gene; LGE = late gadolinium enhancement; LV = left
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diagnosis of the broader spectrum of the disease phenotypes which in-
cludes left-sided variants; iii) the lack of tissue characterization findings
byCE-CMRwhich offers the potential to identifymyocardialfibrosis and
play a key role for accurate diagnosis of the LV phenotype.
The present report represents a further step toward the necessary
upgrading of the criteria for diagnosis of the entire spectrum of pheno-
typic variants of ACM and provides a modern clinical flow-chart for the
diagnosis of ACM. The proposed criteria derive from the diagnostic ap-
proach to ACM, which has been developed over 30 years by the multi-
disciplinary team of basic researchers and clinical cardiologists of the
Medical School of the University of Padua. The writing panel was
enriched by the inclusion of International Experts.
1.1. Definition and classification
“Arrhythmogenic Cardiomyopathy” is currently defined as a genetic
heart muscle disease which affects the RV, the LV or both, whose most
distinctive phenotypic feature is myocardial scar (fibro or fibrofatty
myocardial replacement) which underlies global and/or regional ven-
tricular dysfunction and predisposes to potentially lethal scar-related
ventricular arrhythmias, regardless of the severity of the systolic ven-
tricular dysfunction [8,20]. While the adjective “arrhythmic” refers to
the nonspecific outcome of every heart disease which manifests with
rhythm and conduction disturbances, the adjective “arrhythmogenic”
(the suffix -genic according to its etymology from ancient Greek -
γενής means “tending to generate” arrhythmias) is disease-specific
and denotes the distinctive propensity of ACM to develop ventricular ar-
rhythmias, as a clinical reflection of the underlying fibro-fatty myocar-
dial replacement which is the pathologic hallmark of the disease.
The current classification of ACM includes the following phenotypic
variants: [19] (i) the “dominant-right” variant, i.e., the classic ARVC phe-
notype characterized by the predominant RV involvement, with no or
minor LV abnormalities; (ii) the “biventricular disease” variant” charac-
terized by the parallel involvement of the RV and LV; and (iii) the “dom-
inant-left “variant (also referred to as “arrhythmogenic left ventricular
cardiomyopathy; ALVC”) characterized by the predominant LV involve-
ment, with no or minor RV abnormalities.
Recently, an expert panel of the Heart Rhythm Society (HRS) has
provided a broader definition of ACMas an “arrhythmogenic heartmus-
cle disorder not explained by ischemic, hypertensive, or valvular disease
[21]. ACM incorporates a broad spectrum of systemic (i.e., sarcoidosis,
amyloidosis), inflammatory (i.e., myocarditis), an infectious
(i.e., Chagas disease), or genetic (e.i., desmosomal ARVC or arrhythmo-
genic left ventricular cardiomyopathy [ALVC], lamin A/C, filamin-C,
phospholamban) disorders and ion channel diseases” [21]. According
to the HRS document perspective, the common denominator of all
these conditions is the “clinical presentation with symptoms or docu-
mentation of atrial fibrillation, conduction disease, and/or RV and/or
LV arrhythmia”. There is a general agreement among the panelists of
the present document that the “arrhythmic clinical presentation” does
not provide a pathobiologically and clinically appropriate rationale for
a re-definition of ACM as a non-specific entity which includes a miscel-
laneous group of heterogeneous heart muscle diseases.
2. Diagnostic criteria
Similar to the previous 1994 and 2010 scoring systems (Online Sup-
plemental Tables 1) [4,22], the Padua criteria for diagnosis of ACM are
based on a multi-parametric approach encompassing functional and
structural ventricular abnormalities, tissue characterization findings,
depolarization and repolarization electrocardiographic alterations and
ventricular arrhythmias, and familial/genetic background which are
grouped into 6 categories.
Table 1 summarizes the “Padua criteria” for each category for diag-
nosis of both the RV and LV involvement. The criteria reported in theleft column represent an upgrade of the 2010 International Task Force
(ITF) diagnostic criteria for the classic right-dominant ACM (ARVC),
while those reported in the right column are new criteria for diagnosis
of left-sided ACM (ALVC).
The novelty of the Padua diagnostic criteria essentially consists in
the introduction of tissue characterization by CE-CMR for detection of
fibro-fatty myocardial replacement of both ventricles.
and the addition of new ECG criteria, including depolarization/ repo-
larization abnormalities and ventricular arrhythmias, specific for the LV
involvement.
The accuracy of diagnostic criteria for left-sided ACM varies accord-
ing to the disease variant, whether biventricular or left-dominant. In the
context of biventricular ACM, the disease-specificity of the left-sided ab-
normalities is ensured by the concomitant fulfilment of ITF criteria for
the RV phenotype. Hence, in patients who meet the upgraded 2010 di-
agnostic criteria for the RV phenotype, “biventricular” ACM can be rea-
sonably diagnosed on the basis of phenotypic features of LV
involvement, mostly morpho-functional and structural LV abnormali-
ties. On the other hand, in patientswith no (orminor) clinical RV abnor-
malities (not fulfilling the upgraded 2010 ITF criteria), the diagnosis of
left-dominant ACM (ALVC) cannot be achieved on the basis of the LV
phenotypic criteria only. In fact, morpho-functional and structural LV
abnormalities of ACM do not provide a sufficient disease-specificity be-
cause of the overlapwith the phenotypic features of other heart muscle
diseases such as DCM, myocarditis, or cardiac sarcoidosis. Hence,
diagnosis of “left-dominant” ACM requires, in addition to consistent
LV phenotypic features, the demonstration of a positive genotyping for
ACM-causing gene-mutation.
The approach used in the 1994 and 2010 ITF scoring systems for clas-
sifyingmorpho-functional, structural, histological, ECG, arrhythmic, and
genetic features of the ARVC as “major” and “minor “criteria on the basis
of their disease-specificity is maintained in the Padua criteria. With re-
gard to the newly proposed diagnostic criteria for LV involvement,
they are classified as “major”when they are deemed specific and neces-
sary for diagnosis and “minor” when they are not required, but contrib-
ute to refine the characterization of the LV phenotype.
At variance with genetically-determined cardiac ion channel disor-
ders, pathogenic mutations, ECG abnormalities or arrhythmias are not
sufficient for diagnosis of ACM, which is a structural heart muscle dis-
ease. By analogy with the diagnosis of hypertrophic cardiomyopathy,
that requires demonstration of critical LV hypertrophy [23], at least
one RV or LV criterion from categories I (i.e., morpho-functional ventric-
ular abnormalities) or II (i.e., structural myocardial abnormalities), ei-
ther major or minor is mandatory to reach a diagnosis of ACM
according to the Padua criteria (Fig. 2).
2.1. Morpho-functional ventricular abnormalities (i.e., global and regional
ventricular dilatation and systolic dysfunction)
Right ventricle: Previous distinction of morpho-functional criteria in
major andminor, based on the severity of global RV dilatation and dys-
function, appears more useful for prognostic than for diagnostic pur-
poses and has been eliminated. The upgraded 2010 diagnostic criteria
have been simplified to include only one major morpho-functional cri-
terion, which is fulfilled when regional wall motion abnormalities,
such as RV akinesia, dyskinesia or bulging are associated with either
RV dilatation or dysfunction, regardless of their severity. In addition, a
new minor morpho-functional criterion has been introduced which is
met by the demonstration of regional RV wall motion abnormalities in
the absence of RV dilatation and/or systolic dysfunction. The introduc-
tion of this latter criterion aims to increase the diagnostic sensitivity in
a sizeable proportion of patients who show consistent RV wall motion
abnormalities with normal global cavity size and preserved systolic
function. This pattern reflects the segmental nature of RV lesions
which may manifest as areas of fibro-fatty myocardial replacement
that may alter the regional contractility without compromising the
Table 1
“Padua criteria” for diagnosis of Arrhythmogenic Cardiomyopathy.
Category Right ventricle (upgraded






By echocardiography, CMR or angiography:
Major
• Regional RV akinesia, dyskinesia, or bulging plus one of the following:
- global RV dilatation (increase of RV EDV according to the imaging test
specific nomograms)
- global RV systolic dysfunction (reduction of RV EF according to the
imaging test specific nomograms)
Minor
• Regional RV akinesia, dyskinesia or aneurysm of RV free wall
By echocardiography, CMR or angiography:Minor
• Global LV systolic dysfunction (depression of LV EF or reduction of echo-
cardiographic global longitudinal strain), with or without LV dilatation
(increase of LV EDV according to the imaging test specific nomograms for
age, sex, and BSA)
Minor





• Transmural LGE (stria pattern) of
≥1 RV region(s) (inlet, outlet, and apex in 2 orthogonal views)
By EMB (limited indications):Major
• Fibrous replacement of the myocardium in ≥1 sample, with or without
fatty tissue
By CE-CMR:Major
• LV LGE (stria pattern) of ≥1 Bull's Eye segment(s) (in 2 orthogonal views)
of the free wall (subepicardial or midmyocardial), septum, or both




• Inverted T waves in right precordial leads (V1,V2, and V3) or beyond in
individuals with complete pubertal development (in the absence of
complete RBBB)
Minor
• Inverted T waves in leads V1 and V2 in individuals with completed
pubertal development (in the absence of complete RBBB)
• Inverted T waves in V1,V2,V3 and V4 in individuals with completed
pubertal development in the presence of complete RBBB.
Minor





• Epsilon wave (reproducible low-amplitude signalsbetween end of QRS
complex to onset of the T wave) in
the right precordial leads (V1 to V3)
• Terminal activation duration of QRS ≥55 ms measured from the nadir
of the S wave to the end of the QRS, including R', in V1, V2, or V3 (in the
absence of complete RBBB)
Minor
• Low QRS voltages (b0.5 mV peak to peak) in limb leads (in the absence of




• Frequent ventricular extrasystoles (N500 per 24 h), non-sustained or
sustained ventricular tachycardia of LBBB morphology
Minor
• Frequent ventricular extrasystoles (N500 per 24 h), non-sustained or
sustained ventricular tachycardia of LBBB morphology with inferior
axis (“RVOT pattern”)
Minor
• Frequent ventricular extrasystoles (N500 per 24 h), non-sustained or





• ACM confirmed in a first-degree relative who meets diagnostic criteria
• ACM confirmed pathologically at autopsy or surgery in a first degree relative
• Identification of a pathogenic or likely pathogenetic ACM mutation in the patient under evaluation
Minor
• History of ACM in a first-degree relative in whom it is not possible or practical to determine whether the family member meets diagnostic criteria
• Premature sudden death (b35 years of age) due to suspected ACM in a first-degree relative
• ACM confirmed pathologically or by diagnostic criteria in a second-degree relative
ACM=arrhythmogenic cardiomyopathy; BSA=body surface area; EDV=end diastolic volume; EF= ejection fraction; ITF= International Task Force; LBBB= left bundle-branch block;
LGE = late gadolinium enhancement; LV = left ventricle; RBBB= right bundle-branch block; RV = right ventricle; RVOT= right ventricular outflow tract.
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tic power of this criterion is explained by the limited specificity of the
subjective evaluation of wall motion abnormalities on echocardiogra-
phy and CMR imaging.
In the 2010 ITF criteria, reference values of normal RV end-diastolic
volumes (up to 110 ml/m2 in men and 100ml/m2 in women) were de-
rived from 462 healthy controls of the multiethnic study of atheroscle-
rosis (MESA), in which quantification of ventricular volumes was
obtained using the older fast gradient echo CMR cine technique that un-
derestimates volumes because of incomplete and lower endocardial
border definition [4]. Cardiac chamber volumes are more accurately
measured by the modern CMR cine technique with steady-state free
procession (SSFP) images which provides superior contrast betweenblood and endocardium at the endocardial border with less blood flow
dependence [27,28]. Diagnostic accuracy of both echocardiography
and cine-CMR imaging findings is increased by the use of reference
values for RV cavity size and systolic function normalized for age, sex
and body surface area (BSA), according to current nomograms provided
by international societies of cardiovascular imaging [28].
It is noteworthy that the cut-off values of RV dilatation may lack
specificity in the athletic population because physiologic adaptive
changes of the RV in athlete's heart may produce an increase of RV vol-
ume that goes well beyond the upper limit of normality reported in the
general population [19]. In this regard, proper reference values for RV
volume in the athlete's heart are currently available and should be
used in the differential diagnosis of physiologic versus pathologic RV
Fig. 2. Diagnosis of phenotypic variants of ACM in patients fulfilling the Padua criteria. Demonstration of morpho-functional and/or structural ventricular abnormalities is required for
diagnosis of each phenotypic variant of ACM. Although dominant-right (ARVC) and biventricular disease variants can be diagnosed in those patients fulfilling RV and LV phenotypic
criteria, the diagnosis of dominant-left (ALVC), without clinically demonstrable RV abnormalities, needs demonstration of an ACM-causing gene-mutation, in association with a
consistent LV phenotype(see text for details)
110 D. Corrado et al. / International Journal of Cardiology 319 (2020) 106–114dilatation in athletes, especially if engaged in sports such as rowing or
canoeing associated with the greatest RV dimensional remodeling [29].
Left ventricle: Demonstration of LV systolic dysfunction (by depres-
sion of LV ejection fraction or reduction of LV global longitudinal strain),
with or without LV dilatation is aminormorpho-functional criterion for
diagnosing “biventricular” or “dominant-left” disease variants. This cri-
terion is classified as minor because of its low disease-specificity. Most
patients show regional LV involvementwithout an increase of the cavity
size and/or reduction of the global systolic function as a result of the seg-
mental and non transmural (subepicardial/midmyocardial) fibro-fatty
scar [8–19]. It is recommended the use of reference values for LV cavity
size and systolic function according to current nomograms provided by
international societies of cardiovascular imaging [27]. The imaging evi-
dence of a regional LV wall hypokinesia or akinesia (rarely dyskinesia)
with a preserved LV global systolic function is also considered a minor
morpho-functional criteria.Strain echocardiography has the ability to
detect subtle changes and is useful in early disease [30,31].
2.2. Structural myocardial abnormalities (i.e., fibrous or fibro-fattymyocar-
dial replacement)
Structural myocardial abnormalities of both ventricles are routinely
investigated by CE-CMR, which has become the leading imagingmodal-
ity for ACM diagnosis due to its capability of tissue characterization
[2,30,31].
Although direct tissue characterization is obtained only by
endomyocardial biopsy (EMB), the invasive nature and the potential
risk of serious complications (although rare and occurring in low vol-
ume cardiovascular centers) of this technique limit its indication to se-
lected cases of non-familial ACM for differential diagnosis with disease
phenocopies [19]. Specifically, EMB is indicated in probands with a
sporadic form of ACM and negative genotyping, in whom the ultimate
diagnosis depends on histologic study of the myocardium to exclude
mimics such asmyocarditis, sarcoidosis or other heartmuscle disorders.
Histologic demonstration of replacement-type fibrosis, with or without
fatty tissue, on EMB samples remains a major structural criterion for di-
agnosis. The distinction of EMB findings in “major” and “minor” appearsnot longer justified [32]. Due to possible sampling error, negative EMB
findings do not exclude the diagnosis of ACM. Because the risk/benefit
ratio of LV EMB is not known, at the present time this approach is not
indicated for diagnosis of ACM.
Right ventricle: Tissue characterization by CE-CMR offers the poten-
tial to demonstrate the presence of RV myocardial LGE/fibrosis, with
or without fatty tissue replacement on dedicated sequences. Tissue
characterization findings by CE-CMR were not included in the previous
2010 ITF criteria because of the limited experience in their interpreta-
tion one decade ago. The assessment of LGE or fatty tissue in the thin
RV free wall was considered difficult to the low resolution of CMR
equipment, the protocol design, the inversion time set to null the LV
myocardium and the inversion recovery sequence not fat suppressed
[2]. Despite these limitations, the yield of RV LGE in ACM patients has
been reported up to 88%, indicating that demonstration of LGE in the
RV wall provides a significant added diagnostic value [26,33–35]. The
current availability of new generation CMR equipment with updated
pulse sequences offers the potential to further enhance the accuracy
for the identification of RV intramyocardialfibro-fatty scar tissue [2]. Re-
cent studies demonstrated the usefulness of combined regional wall
motion assessment and tissue characterization by CMR for the diagnosis
of ACM. The highest accuracy (98%) is achievedwhenwallmotion alter-
ations and pre/post-contrast signal abnormalities are considered to-
gether [36]. Accordingly, the demonstration of regional RV LGE
(confirmed in two orthogonal planes, i.e. horizontal long-axis and
short-axis views)with transmural involvement of the RV free wall is in-
cluded in our upgrade of the 2010 criteria and classified as a major
structural myocardial criterion. Indeed, it increases the specificity of
the interpretation of RV wall motion abnormalities by demonstrating
an underlying myocardial scar.
Left ventricle: Tissue characterization findings by CE-CMR offers the
unique potential to diagnose the condition in all affected patients with
LV involvement the presence of LGE/fibrosis, localized in the
subepicardial (less often the mid-myocardial) layers of the LV free
wall and most often affecting the inferolateral regions, with or without
septal involvement [2,8–18]. The coexistence of fatty myocardial infil-
tration is often observed on dedicated sequences in the same regions
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pattern resulting from this fibro(−fatty) myocardial scar involvement
consists of an hypokinetic (or normokinetic) LV, with no or mild cavity
dilatation [2,12,13,18]. LV systolic dysfunctionmay becomemore severe
in the advanced stages, being directly related to the disease progression
and increasing extent of LGE, affecting multiple segments of the LV free
wall and septum, with a more transmural involvement [18].
Although all patients with LV involvement show LV LGE on CE-CMR,
a sizeable proportion of them do not have associated global LV systolic
dysfunction or overt wall motion abnormality [2,8–10,18,24,37,38].
Hence, tissue characterization plays a key role allowing identification
of LGE/fibrosis which is a the most sensitive feature for diagnosis of
left-sided ACM. As a corollary, LV involvement cannot be ruled out
based solely on imaging findings negative for LV functional abnormali-
ties on echo, cine-CMR or angiography. Accordingly, demonstration of
LV myocardial LGE/fibrosis in the form of a stria (or band) pattern af-
fecting ≥1 segment (on the traditional “Bull's Eye” system) is a major
and needed structural criterion for diagnosis of left-sided ACM.
Of importance, the pattern of “junctional” LGE, which is character-
ized by focal/patchy involvement of the posterior (or less frequently an-
terior) ventricular septum at the site of RV attachment, is excluded from
the diagnosis of ACM because of its non-pathologic nature [38].
2.3. ECG depolarization abnormalities
Late potentials on SAECG are not longer included among the Padua
criteria, since the use of SAECG technique has been abandoned by
most centres because of its non-specific findings and limited diagnostic
accuracy [2].
Right ventricle: The presence of epsilon waves in right precordial
leads was classified as major ECG criterion in both the 1994 and the
2010 ITF criteria. However, diagnostic value of the epsilon wave has
been questioned in the last decade, because its identification and inter-
pretation are largely influenced by ECG filtering and sampling rate, giv-
ing rise to large interobserver variability [39]. Among the Padua
diagnostic criteria for ACM, epsilon waves in right precordial leads are
classified as aminor ECG criterion, likewise the ECG pattern of a QRS de-
layed S-wave upstroke with TAD ≥55 ms in right precordial leads (par-
ticularly if followed by negative T waves) [4].
Left ventricle: LowQRS voltages in the limb leads (“peak-to-peakQRS
amplitude b0.5 mV) may predict LV involvement in the context of ACM
[12–14,17,18,24]. The mechanism involved in the reduction of QRS
voltages reasonably consists of the decrease of LV myocardial mass by
fibro-fatty replacement, which mostly accounts for the generation of
the electrical activity causing the depolarization current responsible
for the QRS complex. Why it mainly affects the limb leads remains to
be elucidated. The low sensitivity of low QRS voltages (not exceeding
30%) may be explained by a dose-effect relationship between myocar-
dial replacement by fibrofatty scar and reduction in QRS amplitudes in
limb leads. This is in keeping with the finding of significantly higher
number of LV segments affected by LGE in patients with low QRS volt-
ages in limb leads than in those without this ECG abnormality [24]. Be-
cause of its low estimated specificity compared with other diseases and
normal control, lowQRS voltages in the limb leads should be considered
a minor ECG repolarization criterion.
2.4. ECG repolarization abnormalities
Left ventricle: LV involvement can be predicted by the presence of T-
wave inversion in the leads exploring the LV, mostly the left precordial
leads V4-V6 [8,9,18,19,24]. However, this repolarization pattern is clas-
sified as a minor ECG criterion, because of its low disease-specificity.
Most important, the extent of T wave inversion from right precordial
(V1–V3) to left precordial leads (V4–V6) may predict a more severe
RV dilation/dysfunction, rather than the involvement of the LV. As dem-
onstrated by a recent ECG-CMR correlation study [24], a severely dilatedRV is displaced toward the axilla and a greater proportion of the ventri-
cle is positioned under the ECG leads placed more laterally. Hence, the
traditional LV leads (V4–V6) explore the electrical activity of the dilated
and displaced RV rather than that of the LV.
2.5. Ventricular arrhythmias
In the upgraded criteria, premature ventricular beats (PVB) are eval-
uated not only in terms of absolute number (N500 PVB per 24 h) and
complexity (non-sustained or sustained VT), but also with regard to
themorphology of the ectopic QRS [40,41]. Hence, it is important for di-
agnosis to record ventricular arrhythmia morphology on 12-ECG leads
by exercise testing or 12-lead 24-hour Holter monitoring.
Right ventricle: Similarly to non-sustained and sustained VT, PVBs
originating from RV regions other than the right ventricular outflow
tract (RVOT) have greater specificity for ACM (major ventricular
arrhythmia criterion) than those from the RVOT (minor ventricular
arrhythmia criterion).
Left ventricle: Ventricular arrhythmias with a RBBB morphology
(suggesting the origin from the LV) may be an ECG marker of LV in-
volvement (minor ventricular arrhythmia criterion) [8,9,18,19,24].
2.6. Family history/molecular genetics
According to the expert recommendations for genetic testing in ACM,
genotyping is indicated to identify a pathogenic or likely pathogenic muta-
tion in a proband with consistent phenotypic features of the disease and to
applymutation-specific cascade genetic testing for detection of gene carriers
among family members in order to identify genetically affected individuals
at a preclinical phase [2,42]. The limitations of current understanding of
the genetic basis of ACM and the high genetic noise due to frequent disease
associated genetic variants both in the normal population and other cardio-
myopathies pose the risk of misdiagnosis due to potential misinterpretation
ofmolecular genetic results [43,44].Accordingly, confirmatorygenotyping to
achieve a diagnosis in a patient with borderline phenotypic manifestations
maybe considered in selected cases provided that the results are interpreted
by experts on the molecular genetics of ACM [45].
While in patients with biventricular ACM is the concomitant fulfil-
ment of RV diagnostic criteria to guarantee the disease-specificity of
the left-sided abnormalities, in patients with left-dominant ACM and
no clinically detectable RV involvement, demonstration of a pathogenic
mutation in ACM-related genes (major criterion) is necessary for diagno-
sis, because it is the most specific finding linking the LV phenotypic fea-
tures to ACM.
3. Diagnosis of phenotypic variants of ACM
The following diagnostic score for diagnosis of phenotypic variants
of ACM is proposed on the basis of the Padua criteria (Fig. 2). A diagnosis
of ARVC (“dominant right” variant) is met in patients fulfilling the RV
criteria for "definite"i.e., 2 major, 1 major and 2 minor, or 4 minor
criteria from different categories; "borderline",i.e., 1 major and 1
minor, or 3 minor criteria from different categories; or "possible"
ARVC, i.e., 1 major or 2 minor criteria from different categories (≥1
morpho-functional and/or structural criteria, either major or minor,
nedeed for each degree of diagnosis), in the absence of LV involvement.
The diagnosis of definite, borderline or possible “biventricular” variant
(i.e., involvement of both ventricles) requires the fulfilment of ≥1
morpho-functional and/or structural abnormalities of both the RV and
LV. The diagnosis of ALVC (“dominant-left” variant) is met in patients
who show structural (with or without morpho-functional) abnormali-
ties of the LV, plus demonstration of a ACM-causing gene-mutation, in
the absence of RV involvement (Fig. 3 summarizes the proposed
flow-chart for clinical diagnosis of ACM, which is based on the Padua
protocol for management of probands and families.
Fig. 3. Proposed flow-chart for clinical diagnosis of ACM. Patients with a suspicion of ACM because of family history, symptoms, ECG abnormalities, ventricular arrhythmias, or imaging
features undergo a non-invasive clinical evaluation which includes 12-lead ECG, echocardiography, exercise testing, and 24-hour Holter monitoring. In addition, morpho-functional
ventricular abnormalities and structural myocardial tissue alterations are routinely investigated by contrast-enhanced CMR, which has become the leading imaging modality for
diagnosis and characterization of the disease phenotype, with particular reference with the left-sided variants. Transthoracic two-dimensional echocardiography is indicated as part of
the initial evaluation of a patient with suspected ACM. The availability of echocardiographic findings at initial evaluation is important in view of the subsequent serial imaging follow-
up. Right ventricular angiography is not of additional diagnostic value and is reserved to patients in whom endomyocardial biopsy is planned. Cardiac catheterization is indicated
when oxygen saturation measurement is required for differential diagnosis between ACM and congenital heart diseases with a left to right shunt, if the CMR findings are inconclusive.
Clinical and molecular genetic screening is performed for identifying the ACM-causing genetic defect, drawing a pedigree and making a preclinical diagnosis among family members.
Based on molecular genetic testing, the disease can be related to ACM-causing mutations of either desmosomal or non-desmosomal genes. Gene elusive and non-familial disease,
requires further evaluation to exclude mimics, including congenital phenocopies such as left-to-right shunt or Ebstein anomaly, and acquired phenocopies such as idiopathic dilated
cardiomyopathy, cardiac sarcoidosis, myocarditis, pulmonary artery hypertension, or Chagas disease.
112 D. Corrado et al. / International Journal of Cardiology 319 (2020) 106–1144. Conclusions
Over the last decade there has been an increasing awareness that the
phenotypic spectrum of ACM was broader than previously expected
and included biventricular and left-dominant variants. The lack ofspecific ITF diagnostic criteria resulted in the under-recognition of pa-
tients with the non-classic ARVC phenotype. The Padua criteria repre-
sent a working framework to improve the diagnosis of ACM with the
aim to fill the gap of previous 1994 and 2010 ITF criteria, by introducing
new diagnostic criteria regarding CE-CMR tissue characterization
113D. Corrado et al. / International Journal of Cardiology 319 (2020) 106–114findings, depolarization/repolarization ECG abnormalities and ventricu-
lar arrhythmia features for diagnosis of the LV phenotype. The proposed
diagnostic criteria need to be validated by further clinical studies in
large cohorts of patients. Future research should focus on a better un-
derstanding of the genetic background, the identification of diagnostic
biomarkers and the evaluation of natural history, risk stratification
and management of patients diagnosed with left-sided ACM.
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.ijcard.2020.06.005.
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